Orchid Pharma cash flow

Latest FY26

Cash from operations: ₹126cr+553.8% on FY25
Capital spending: ₹390cr+159.6% on FY25
Free cash flow: −₹264cr−₹131 cr in FY25
Cash from financing: ₹137cr+443.7% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	43.2	34.5	33.2	54.8
	—	9.0	14.5	16.4	32.2
	—	8.9	0.0	0.0	−0.4
	—	0.0	0.0	0.0	0.0
	—	−8.2	−5.8	7.6	1.6
	—	0.7	0.0	0.0	0.0
	—	0.9	0.0	−41.2	0.0
	—	0.0	0.0	0.0	−0.0
	—	−32.4	0.0	0.7	0.0
	—	85.1	−62.1	−35.5	−56.1
	—	−39.6	−49.1	19.6	−41.7
	—	0.0	6.8	0.0	0.0
	—	0.5	1.7	0.0	0.0
	—	−18.6	4.5	0.0	1.6
	—	0.0	0.3	0.0	0.0
	—	29.2	0.0	54.9	13.9
	—	0.0	−6.8	0.0	0.0
	—	0.0	0.0	−7.3	−5.8
	—	0.0	0.0	−0.3	1.2
	—	14.3	3.2	0.0	0.0
Cash from operating activities
	12.0	10.4	95.6	91.9	55.2
	—	105	−58.1	51.0	3.6
	—	115	37.4	143	58.9
	—	0.0	0.0	−16.3	0.0
	—	0.0	17.3	0.0	0.0
	—	7.9	0.0	0.0	−40.0
	—	−2.4	0.9	0.6	0.3
	—	126	19.2	126	18.6
Cash from investing activities
	—	390	150	−64.8	84.9
	—	9.1	0.0	0.0	0.9
	—	0.0	0.0	4.3	0.0
	—	0.0	0.0	0.0	57.6
	—	1.1	0.0	0.0	−1.0
	—	22.6	0.0	0.0	0.0
	—	0.0	104	0.0	0.0
	—	0.0	0.0	0.0	0.0
	—	12.2	18.7	12.0	0.2
	—	113	0.0	−385	−4.3
	—	−277	−26.9	−312	−31.5
Cash from financing activities
	—	0.0	0.0	392	0.0
	—	170	28.6	0.0	173
	—	22.9	0.2	209	110
	—	10.1	3.1	16.4	32.2
	—	137	25.2	167	31.2
	—	−14.1	17.5	−19.0	18.3
	—	−14.1	17.5	−19.0	18.3
	—	—	—	3.6	22.6
Reference items
	44.2	33.6	117	111	83.6
	4.1%	2.7%	12.7%	13.5%	12.6%
	−264	−264	−131	61.2	−66.3
	—	−147	−94.2	−152	—
	−₹44.08	−₹44.08	−₹21.86	₹10.22	−₹11.08
	—	12.62×	0.19×	1.37×	0.40×
	—	−2.4	0.9	0.6	0.3
	—	10.1	3.1	16.4	32.2

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

ORCHPHARMA₹865.00

Orchid Pharma Limited

· Pharma & Health

₹ CrorePeersFDC GUJTHEM IOLCP MOREPENLAB RPGLIFE GUFICBIO INNOVACAP UNICHEMLABMcap ₹5,180 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	54.8	33.2	34.5	43.2	—
+ Finance Costs	32.2	16.4	14.5	9.0	—
+ Interest Income	-0.4	0.0	0.0	8.9	—
+ Dividend Income	0.0	0.0	0.0	0.0	—
+ Unrealised FX (Gain) / Loss	1.6	7.6	-5.8	-8.2	—
+ Undistributed Profits of Associates	0.0	0.0	0.0	0.7	—
+ Other Non-cash Items	0.0	-41.2	0.0	0.9	—
+ Other — Cash Effects are Investing / Financing	-0.0	0.0	0.0	0.0	—
+ Other Reconciling Items	0.0	0.7	0.0	-32.4	—
Changes in Working Capital
+ Inventories	-56.1	-35.5	-62.1	85.1	—
+ Trade Receivables — Current	-41.7	19.6	-49.1	-39.6	—
+ Trade Receivables — Non-current	0.0	0.0	6.8	0.0	—
+ Other Financial Assets — Non-current	0.0	0.0	1.7	0.5	—
+ Other Current Assets	1.6	0.0	4.5	-18.6	—
+ Other Non-current Assets	0.0	0.0	0.3	0.0	—
+ Trade Payables — Current	13.9	54.9	0.0	29.2	—
+ Trade Payables — Non-current	0.0	0.0	-6.8	0.0	—
+ Other Current Liabilities	-5.8	-7.3	0.0	0.0	—
+ Provisions — Current	1.2	-0.3	0.0	0.0	—
+ Provisions — Non-current	0.0	0.0	3.2	14.3	—
Cash from Operating Activities
Profit Before Tax (per I/S)	55.2	91.9	95.6	10.4	12.0
+ Total Adjustments (incl. Working Capital)	3.6	51.0	-58.1	104.9	—
Cash from Operations (pre-tax)	58.9	143.0	37.4	115.4	—
+ Interest Received — Operating	0.0	-16.3	0.0	0.0	—
+ Interest Paid — Operating	0.0	0.0	17.3	0.0	—
+ Other Inflows / (Outflows) — Operating	-40.0	0.0	0.0	7.9	—
+ Income Taxes Paid	0.3	0.6	0.9	-2.4	—
Cash from Operating Activities	18.6	126.0	19.2	125.6	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	84.9	-64.8	150.1	389.6	—
+ Disp of Fixed Assets	0.9	0.0	0.0	9.1	—
+ Acq of Other Long-term Assets	0.0	4.3	0.0	0.0	—
+ Disp of Other Long-term Assets	57.6	0.0	0.0	0.0	—
+ Sale of Investments (Equity / Debt)	-1.0	0.0	0.0	1.1	—
+ Investment in Partnership Firms / LLPs	0.0	0.0	0.0	22.6	—
+ Receipts on Futures / Forwards / Options / Swaps	0.0	0.0	104.4	0.0	—
+ Dividends Received — Investing	0.0	0.0	0.0	0.0	—
+ Interest Received — Investing	0.2	12.0	18.7	12.2	—
+ Other Inflows / (Outflows) — Investing	-4.3	-384.6	0.0	113.0	—
Cash from Investing Activities	-31.5	-312.0	-26.9	-276.9	—
Cash from Financing Activities
+ Proceeds from Issue of Shares	0.0	391.9	0.0	0.0	—
+ Proceeds from Borrowings	173.2	0.0	28.6	170.1	—
+ Repayment of Borrowings	109.8	208.5	0.2	22.9	—
+ Interest Paid	32.2	16.4	3.1	10.1	—
Cash from Financing Activities	31.2	167.0	25.2	137.1	—
Net Changes in Cash (pre-FX)	18.3	-19.0	17.5	-14.1	—
Net Changes in Cash	18.3	-19.0	17.5	-14.1	—
Closing Cash	22.6	3.6	—	—	—
Reference Items
EBITDA	83.6	110.7	117.2	33.6	44.2
EBITDA Margin %	12.56	13.51	12.71	2.72	4.12
Free Cash Flow (CFO − Capex)	-66.3	61.2	-130.9	-264.0	-264.0
Free Cash Flow to Equity	—	-152.0	-94.2	-146.9	—
Free Cash Flow per Basic Share	-11.08	10.22	-21.86	-44.08	-44.08
Cash Flow to Net Income	0.40	1.37	0.19	12.62	—
Cash Paid for Taxes	0.3	0.6	0.9	-2.4	—
Cash Paid for Interest	32.2	16.4	3.1	10.1	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.